
The Committee for Medicinal Products for Human Use (CHMP) adopted positive opinions on initial marketing authorisation applications for: *	Exubera (insulin human), Aventis/Pfizer EEIG. Exubera is human insulin that is administered through inhalation. It is indicated for the treatment of adult patients with Type 2 diabetes mellitus who are not adequately controlled with oral antidiabetic agents and require insulin therapy... click link for more info.

